FierceBiotechOriginal article
{"a":[{"_":"Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex","$":{"href":"/biotech/sionnas-cystic-fibrosis-flop-significant-positive-vertex","hreflang":"en"}}]}
Phase 2negativeNegative
AI Analysis
Summary
Sionna Therapeutics terminated its cystic fibrosis add-on program after failing a Phase 2 trial, causing a 90% stock decline. The company plans to preserve capital and evaluate next steps.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Phase 2 trial failure for cystic fibrosis add-on program
Importance:6/10
Sentiment:
-0.90
Phase 2 failurecystic fibrosisprogram terminationstock declinecapital preservation
Related Companies
Read the original article
Published by FierceBiotech on August 10, 2026 9:39 AM